Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG.

about

Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG.

Item

http://www.wikidata.org/entity/Q41762575

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Functional imaging of pharmaco ...... via PET imaging using 11C-MDG.

@en

type

Item

label

Functional imaging of pharmaco ...... via PET imaging using 11C-MDG.

@en

prefLabel

Functional imaging of pharmaco ...... via PET imaging using 11C-MDG.

@en

P1476

Functional imaging of pharmaco ...... via PET imaging using 11C-MDG.

@en

P2093

Akihiro Noda

http://www.w3.org/2001/XMLSchema#string

Keisuke Mitsuoka

http://www.w3.org/2001/XMLSchema#string

Masanori Yokono

http://www.w3.org/2001/XMLSchema#string

Nobuhiro Umeda

http://www.w3.org/2001/XMLSchema#string

Shoji Takakura

http://www.w3.org/2001/XMLSchema#string

Sosuke Miyoshi

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Takasu

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Murakami

http://www.w3.org/2001/XMLSchema#string

Yuka Hayashizaki

http://www.w3.org/2001/XMLSchema#string

P2860

The Crystal Structure of a Sodium Galactose Transporter Reveals Mechanistic Insights into Na+/Sugar Symport

Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

Ipragliflozin: first global approval.

Functional expression of SGLTs in rat brain

Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.

Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.

P304

e00244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PRP2.244

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28116097

http://www.w3.org/2001/XMLSchema#string

P932

5242169

http://www.w3.org/2001/XMLSchema#string